Pliant Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 158
- Market Cap
- $797.1M
- Website
- http://www.pliantrx.com
- Introduction
Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-?1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.
Idiopathic pulmonary fibrosis promising drugs: FOXO3 and beyond
Refoxy Pharma secures $9.58 million to develop IPF drug RP-01 targeting FOXO3. Boehringer Ingelheim plans NDA submission for nerandomilast. Insilico's ISM001-055 and Endeavor's ENV-101 show disease improvement. Vicore's buloxibutid and BMS' BMS-986278 also chart progress. Pliant's bexotegrast mitigates chronic cough in IPF. IPOs and partnerships fuel IPF therapeutic field.
Pliant Therapeutics to Participate in the Stifel Healthcare Conference
Pliant Therapeutics announces CFO Keith Cummings and Greg Cosgrove will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Nov 19, 2024. The event will be webcast live and archived for 30 days.
AI-Designed Insilico Drug Flashes Signs of Efficacy in Lung Disease, But Rivals Are Still Ahead
Insilico Medicine's AI-designed drug ISM001-055 shows positive Phase 2a results for idiopathic pulmonary fibrosis (IPF), with dose-dependent improvement in forced vital capacity (FVC). The drug targets TNIK enzyme, identified via generative AI, and is set for further Phase 2b studies. Competitors include Boehringer Ingelheim's nerandomilast and Pliant Therapeutics' bexotegrast, both showing promising results in IPF treatment.
Insilico Medicine claims phase 2 win for AI-designed drug
Insilico Medicine's lead candidate drug, INS018_055/ISM001-055, met safety and efficacy endpoints in a phase 2a trial for idiopathic pulmonary fibrosis (IPF), with highest dose showing significant improvement in lung function. The company plans a phase 2b trial and will release full data at a medical conference. Insilico specializes in AI-driven drug discovery, with this being the first AI-designed drug to enter phase 2 trials.
© Copyright 2024. All Rights Reserved by MedPath